A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma.
Chenicheri Kizhakkeveettil KeerthanaSreekumar U AiswaryaTennyson P RayginiaYadu VijayanShirley JamesSadiq C ShifanaSankar SundaramD K IndujaRavi S LankalapalliKuzhuvelil B HarikumarRuby John AntoPublished in: Anti-cancer agents in medicinal chemistry (2024)
Our results highlight the potential of Utt-B as an effective chemosensitizer, which can augment the efficacy of Sor against HCC and circumvent Sor-induced toxic side effects. Moreover, this is the first and only report to date on the chemosensitizing potential of Utt-B and the only report that demonstrates the therapeutic efficacy and pharmacological safety of a novel combinatorial regimen involving Utt-B and Sor for combating HCC.